Tasquinimod (Standard)

Tasquinimod (Standard) is the analytical standard of Tasquinimod. This product is intended for research and analytical applications. Tasquinimod is an oral antiangiogenic agent, which has the potential for castration-resistant prostate cancer treatment. Tasquinimod binds to the regulatory Zn2+ binding domain of HDAC4 with Kd of 10-30 nM. Tasquinimod also is a S100A9 inhibitor[1][2][3].

Product Specifications

CAS Number

[254964-60-8]

Product Name Alternative

ABR-215050 (Standard)

UNSPSC

12352005

Target

HDAC; Reference Standards

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Others

Field of Research

Cancer

Smiles

O=C(C1=C(O)C2=C(N(C)C1=O)C=CC=C2OC)N(C)C3=CC=C(C(F)(F)F)C=C3

Molecular Formula

C20H17F3N2O4

Molecular Weight

406.36

References & Citations

[1]Isaacs JT, et al. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res. 2013 Feb 15;73 (4) :1386-99.|[2]Isaacs JT, et al. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment. Oncotarget. 2014 Sep 30;5 (18) :8093-106.|[3]Olsson A, et al. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer. 2010 May 17;9:107.